Advertisement

Current Cardiology Reports

, Volume 11, Issue 4, pp 298–305 | Cite as

Choosing the best contraceptive method for the adult with congenital heart disease

  • Candice K. Silversides
  • Mathew Sermer
  • Samuel C. Siu
Article

Abstract

As women with congenital heart disease (CHD) approach childbearing age, issues such as pregnancy and contraception need to be addressed. Women with CHD represent a heterogeneous population. While some have simple cardiac lesions and thus have contraceptive risks that are no different from those of the general population, others have complex, multisystem disease such that incorrect contraception advice can be associated with serious health consequences. Choosing a contraceptive requires consideration of the risk of pregnancy; the available contraception options; their risks, failure rates, and benefits; and the preferences of the woman. This review focuses on contraceptive selection in women with CHD.

Keywords

Pulmonary Arterial Hypertension Kawasaki Disease Tubal Ligation Fontan Operation Etonogestrel 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Warnes CA, Williams RG, Bashore TM, et al.: ACC/AHA 2008 Guidelines for the Management of Adults With Congenital Heart Disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to develop guidelines on the management of adults with congenital heart disease). Circulation 2008, 118: e714–e833.PubMedCrossRefGoogle Scholar
  2. 2.
    Siu SC, Sermer M, Colman JM, et al.: Prospective multicenter study of pregnancy outcomes in women with heart disease. Circulation 2001, 104:515–521.PubMedCrossRefGoogle Scholar
  3. 3.
    Siu SC, Colman JM: Heart disease and pregnancy. Heart 2001, 85:710–715.PubMedCrossRefGoogle Scholar
  4. 4.
    Uebing A, Steer PJ, Yentis SM, Gatzoulis MA: Pregnancy and congenital heart disease. BMJ 2006, 332:401–406.PubMedCrossRefGoogle Scholar
  5. 5.
    Drenthen W, Pieper PG, Roos-Hesselink JW, et al.: Outcome of pregnancy in women with congenital heart disease: a literature review. J Am Coll Cardiol 2007, 49:2303–2311.PubMedCrossRefGoogle Scholar
  6. 6.
    Trussel J: Contraceptive efficacy. In Contraceptive Technology, edn 18. Edited by Hatcher R, Trussel J, Stewart F, et al. New York: Ardent Media; 2004:773–845.Google Scholar
  7. 7.
    Kovacs AH, Harrison JL, Colman JM, et al.: Pregnancy and contraception in congenital heart disease: what women are not told. J Am Coll Cardiol 2008, 52:577–578.PubMedCrossRefGoogle Scholar
  8. 8.
    Sidney S, Petitti DB, Soff GA, et al.: Venous thromboembolic disease in users of low-estrogen combined estrogen-progestin oral contraceptives. Contraception 2004, 70:3–10.PubMedCrossRefGoogle Scholar
  9. 9.
    Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1995, 346:1575–1582.Google Scholar
  10. 10.
    Jick H, Jick SS, Gurewich V, et al.: Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995, 346:1589–1593.PubMedCrossRefGoogle Scholar
  11. 11.
    Poulter NR, Chang CL, Marmot M, et al.: Third-generation oral contraceptives and venous thrombosis. Lancet 1997, 349:732.PubMedCrossRefGoogle Scholar
  12. 12.
    Endrikat J, Klipping C, Cronin M, et al.: An open label, comparative study of the effects of a dose-reduced oral contraceptive containing 20 microg ethinyl estradiol and 100 microg levonorgestrel on hemostatic, lipids, and carbohydrate metabolism variables. Contraception 2002, 65:215–221.PubMedCrossRefGoogle Scholar
  13. 13.
    Oelkers W, Foidart JM, Dombrovicz N, et al.: Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J Clin Endocrinol Metab 1995, 80:1816–1821.PubMedCrossRefGoogle Scholar
  14. 14.
    Narkiewicz K, Graniero GR, D’Este D, et al.: Ambulatory blood pressure in mild hypertensive women taking oral contraceptives. A case-control study. Am J Hypertens 1995, 8:249–253.PubMedCrossRefGoogle Scholar
  15. 15.
    Chasan-Taber L, Willett WC, Manson JE, et al.: Prospective study of oral contraceptives and hypertension among women in the United States. Circulation 1996, 94:483–489.PubMedGoogle Scholar
  16. 16.
    Acute myocardial infarction and combined oral contraceptives: results of an international multicentre case-control study. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1997, 349:1202–1209.Google Scholar
  17. 17.
    Lidegaard O: Oral contraceptives, pregnancy and the risk of cerebral thromboembolism: the influence of diabetes, hypertension, migraine and previous thrombotic disease. Br J Obstet Gynaecol 1995, 102:153–159.PubMedGoogle Scholar
  18. 18.
    Margolis KL, Adami HO, Luo J, et al.: A prospective study of oral contraceptive use and risk of myocardial infarction among Swedish women. Fertil Steril 2007, 88:310–316.PubMedCrossRefGoogle Scholar
  19. 19.
    Sidney S, Siscovick DS, Petitti DB, et al.: Myocardial infarction and use of low-dose oral contraceptives: a pooled analysis of 2 US studies. Circulation 1998, 98:1058–1063.PubMedGoogle Scholar
  20. 20.
    World Health Organization: Medical Eligibility Criteria for Contraceptive Use, edn 3. Geneva, Switzerland: World Health Organization; 2004.Google Scholar
  21. 21.
    Gaffield ME, Curtis KM, Mohllajee AP, Peterson HB: Medical eligibility criteria for new contraceptive methods: combined hormonal patch, combined hormonal vaginal ring and the etonogestrel implant. Contraception 2006, 73:134–144.PubMedCrossRefGoogle Scholar
  22. 22.
    ACOG Committee on Practice Bulletins-Gynecology: ACOG practice bulletin. No. 73: use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol 2006, 107:1453–1472.Google Scholar
  23. 23.
    Vis JC, Timmermans J, Post MC, et al.: Increased prevalence of migraine in Marfan syndrome. Int J Cardiol 2008 Aug 2 (Epub ahead of print).Google Scholar
  24. 24.
    Kiesewetter CH, Sheron N, Vettukattill JJ, et al.: Hepatic changes in the failing Fontan circulation. Heart 2007, 93:579–584.PubMedCrossRefGoogle Scholar
  25. 25.
    Miner P: Contraceptive choices for females with congenital heart disease. Prog Pediatr Cardiol 2004, 19:15–24.CrossRefGoogle Scholar
  26. 26.
    Canobbio MM, Perloff JK, Rapkin AJ: Gynecological health of females with congenital heart disease. Int J Cardiol 2005, 98:379–387.PubMedCrossRefGoogle Scholar
  27. 27.
    Thorne S, Nelson-Piercy C, MacGregor A, et al.: Pregnancy and contraception in heart disease and pulmonary arterial hypertension. J Fam Plann Reprod Health Care 2006, 32:75–81.PubMedCrossRefGoogle Scholar
  28. 28.
    Thorne S, MacGregor A, Nelson-Piercy C: Risks of contraception and pregnancy in heart disease. Heart 2006, 92:1520–1525.PubMedCrossRefGoogle Scholar
  29. 29.
    Silversides CK, Granton JT, Konen E, et al.: Pulmonary thrombosis in adults with Eisenmenger syndrome. J Am Coll Cardiol 2003, 42:1982–1987.PubMedCrossRefGoogle Scholar
  30. 30.
    Varma C, Warr MR, Hendler AL, et al.: Prevalence of “silent“ pulmonary emboli in adults after the Fontan operation. J Am Coll Cardiol 2003, 41:2252–2258.PubMedCrossRefGoogle Scholar
  31. 31.
    Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives. Results of an international, multicenter, case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Contraception 1998, 57:315–324.Google Scholar
  32. 32.
    Vasilakis C, Jick H, del Mar Melero-Montes M: Risk of idiopathic venous thromboembolism in users of progestagens alone. Lancet 1999, 354:1610–1611.PubMedCrossRefGoogle Scholar
  33. 33.
    Conard J, Plu-Bureau G, Bahi N, et al.: Progestogen-only contraception in women at high risk of venous thromboembolism. Contraception 2004, 70:437–441.PubMedCrossRefGoogle Scholar
  34. 34.
    Mohllajee AP, Curtis KM, Martins SL, Peterson HB: Hormonal contraceptive use and risk of sexually transmitted infections: a systematic review. Contraception 2006, 73:154–165.PubMedCrossRefGoogle Scholar
  35. 35.
    Peterson HB, Xia Z, Hughes JM, et al.: The risk of pregnancy after tubal sterilization: findings from the U.S. Collaborative Review of Sterilization. Am J Obstet Gynecol 1996, 174:1161–1168; discussion 1168–1170.PubMedCrossRefGoogle Scholar
  36. 36.
    Peterson HB, Xia Z, Wilcox LS, et al.: Pregnancy after tubal sterilization with silicone rubber band and spring clip application. Obstet Gynecol 2001, 97:205–210.PubMedCrossRefGoogle Scholar
  37. 37.
    Duffy S, Marsh F, Rogerson L, et al.: Female sterilisation: a cohort controlled comparative study of ESSURE versus laparoscopic sterilisation. BJOG 2005, 112:1522–1528.PubMedCrossRefGoogle Scholar
  38. 38.
    Famuyide AO, Hopkins MR, El-Nashar SA, et al.: Hysteroscopic sterilization in women with severe cardiac disease: experience at a tertiary center. Mayo Clin Proc 2008, 83:431–438.PubMedCrossRefGoogle Scholar
  39. 39.
    Bedard E, Dimopoulos K, Gatzoulis MA: Has there been any progress made on pregnancy outcomes among women with pulmonary arterial hypertension? Eur Heart J 2009, 30:256–265.PubMedCrossRefGoogle Scholar
  40. 40.
    Weiss BM, Zemp L, Seifert B, Hess OM: Outcome of pulmonary vascular disease in pregnancy: a systematic overview from 1978 through 1996. J Am Coll Cardiol 1998, 31:1650–1657.PubMedCrossRefGoogle Scholar
  41. 41.
    Reid GJ, Siu SC, McCrindle BW, et al.: Sexual behavior and reproductive concerns among adolescents and young adults with congenital heart disease. Int J Cardiol 2008, 125:332–338.PubMedCrossRefGoogle Scholar
  42. 42.
    Leonard H, O’sullivan JJ, Hunter S: Family planning requirements in the adult congenital heart disease clinic. Heart 1996, 76:60–62.PubMedCrossRefGoogle Scholar
  43. 43.
    Rogers P, Mansour D, Mattinson A, O’sullivan JJ: A collaborative clinic between contraception and sexual health services and an adult congenital heart disease clinic. J Fam Plann Reprod Health Care 2007, 33:17–21.PubMedCrossRefGoogle Scholar
  44. 44.
    Moons P, De Geest S, Budts W: Comprehensive care for adults with congenital heart disease: expanding roles for nurses. Eur J Cardiovasc Nurs 2002, 1:23–28.PubMedCrossRefGoogle Scholar

Copyright information

© Current Medicine Group, LLC 2009

Authors and Affiliations

  • Candice K. Silversides
    • 1
  • Mathew Sermer
  • Samuel C. Siu
  1. 1.Toronto General HospitalUniversity of Toronto Pregnancy and Heart Disease Research ProgramTorontoCanada

Personalised recommendations